【摘要】 目的　评价尿核基质蛋白 2 2 (NMP2 2 )在膀胱癌诊断和预后判定中的应用价值。　方法　采用ELISA法测定 18例膀胱癌和 2 0例泌尿系良性疾病患者尿液中NMP2 2值 ,及 10例膀胱移行细胞癌患者术后尿NMP2 2值。　结果　 18例膀胱癌患者尿NMP2 2的中位值为 44 .3IU/L ,2 0例泌尿系良性疾病患者尿NMP2 2的中位值为 5 .8IU/L ,二者相比差别有显著性意义 (P <0 .0 2 )。以10IU/L为临界值 ,诊断膀胱癌的敏感性为 83% ,特异性为 70 % ,阴性预测值为 82 %。 10例膀胱移行细胞癌患者术后尿NMP2 2中位值为 7.8IU/L ,与术前相比明显下降 (P <0 .0 1)。尿NMP2 2在肿瘤分级间的差别无显著性意义。　结论　尿NMP2 2作为一种灵敏、简便的早期诊断膀胱癌的瘤标 ,对于预后判断可能具有应用价值更多还原

【Abstract】 Objective To determine the clinical efficac y of nuclear matrix protein 22(NMP22) as a novel urine marker for bladder cance r. Methods Urine NMP22 values were determined for 18 bla dder cancer patients and 20 urological benign disease patients by an enzyme-lin ked immunosorbent assay (ELISA). Results Median NMP22 va lue for the bladder cancers was 44.3 IU/L vs 5.8 IU/L for urological benign dise ases. The urinary NMP22 values in the bladder cancer group were significantly hi gher than those in the benign condition group (P<0.02). The sensitivity of N MP22 was 83% with a specificity of 70% at a reference value of 10 IU/L. It’s neg ative predictive value was 82%. When urinary NMP22 values were determined pre-a nd postoperatively in 10 bladder cancer patients, the postoperative values decre ased in all patients and were below 10 IU/L in 70% patients. The postoperative m edian NMP22 value was 7.8 IU/L and was significantly lower than preoperative val ue (P<0.01). Urinary NMP22 values and grade of tumors showed no significant correlation. Conclusions Urinary NMP22 value is a sensit ive,simple and noninvasive diagnostic marker for bladder cancer.更多还原